Movember Foundation and Prostate Cancer Canada team up to turn research into results

Two major projects are underway to help men with aggressive disease



July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.

Each set to receive $1.5 million over a 3 year period, the objective of the projects is to accelerate the transition of existing knowledge into clinical application:
 


Targeting a protein that assists a deadly form of prostate cancer

Principal Investigator: Dr. Amina Zoubeidi, Vancouver Prostate Centre, Vancouver Coastal Health Research Institute

Dr. Zoubeidi and her team are focusing on a deadly form of prostate cancer called neuroendocrine prostate cancer (NEPC), for which the only treatment option is a highly toxic chemotherapy and survival is measured in months. Building upon the discovery of a protein that is essential for the growth and survival of NEPC, the team is developing first-in-field blockers of this protein. At the successful completion of this research, they will have fine-tuned an ideal drug that is ready for immediate application in a clinical trial, with the ultimate goal of changing the way NEPC is treated.

Bacteria as a prostate cancer drug delivery service

Principal Investigator: Sylvain Martel, Polytechnique Montréal

Dr. Martel and his team are focused on improving the accuracy and speed of drug-delivery to sites where prostate cancer cells have spread, which will lead to better theraputic effects while reducing toxicity for the patient. In order to accomplish this, they are proposing innovative delivery vehicles that have exceptional propulsion, sensory, and navigation capabilites - bacteria. Using special bacteria that cause no significant immunce response, they will conduct human-scale studies with the aim of introducing these natural nanorobots as key delivery agents in the treatment of prostate cancers.

"The road from research discoveries to real world impact can be long and winding, and it is for that very reason that projects such as these are so exciting," explained Dr. Stuart Edmonds, PCC's Vice President of Research, health Promotion and Survivorship. "After untold amounts of time, money and hard work, we are now in a position to cross the threshold from the lab to the clinic and begin applying the sum total of this research towards improving outcomes for men and their families."

Paul Villanti, the Movember Foundation's Director of Programmes, said "The Movember Foundation's mission is to stop men dying too young, and these two pioneering projects represent an incredible opportunity to do exactly that. It is only through the efforts of our amazing community of fundraisers in Canada that we are in a position to take these promising new treatment methods for men from the lab that vital step closer to clinical practice. We are hugely grateful to these incredible individuals who make such a difference.

About the Movember Foundation

The Movember Foundation is the leading men's health charity, funding over 1,200 projects in 21 countries worldwide -- focused on men's mental health, suicide prevention, testicular and prostate cancer research, and support. To date, Movember has raised over $800 million worldwide to deliver innovative, breakthrough research and support programs that enable men to live happier, healthier and longer lives.

About Prostate Cancer Canada

Prostate Cancer Canada is the leading national foundation dedicated to the elimination of the most common cancer in men through research, advocacy, education, support and awareness. As one of the largest investors in prostate cancer research in Canada, Prostate Cancer Canada is committed to continuous discovery in the areas of prevention, diagnosis, treatment, and support.

For more information, please contact:

Adam Miller
Manager, Communications | Prostate Cancer Canada
Office: 416-441-2131 ext. 235
Email: adam.miller@prostatecancer.ca



Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive